(HOWL) Werewolf Therapeutics - Ratings and Ratios

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) is a biopharmaceutical company specializing in the development of innovative cancer treatments that leverage the bodys immune system. Through its proprietary PREDATOR platform, the company designs conditionally activated molecules engineered to overcome the limitations of conventional proinflammatory immune therapies. These molecules are designed to stimulate both adaptive and innate immunity, offering a more targeted approach to cancer treatment. The companys lead product candidate, WTX-124, is a conditionally activated Interleukin-2 (IL-2) INDUKINE molecule currently in Phase I/Ib clinical trials for the treatment of advanced or metastatic solid tumors. WTX-330, another key candidate, is a conditionally activated Interleukin-12 (IL-12) INDUKINE molecule in Phase I clinical trials for advanced or metastatic solid tumors and lymphoma. Additionally, Werewolf Therapeutics is developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for cancer treatment, as well as WTX-712 (activated IL-21) and WTX-518 (activated IL-18) INDUKINE molecules for cancer. The company was founded in 2017 and is headquartered in Watertown, Massachusetts.

Ticker Symbol: HOWL Exchange: NASDAQ Type: Common Stock Country Origin: United States GICS Sub Industry: Biotechnology

3-Month Forecast (Using Technical and Fundamental Data): Based on the technical data, HOWL is currently trading below its 20-day, 50-day, and 200-day moving averages, indicating bearish momentum. The stocks average trading volume over 20 days is 280,758 shares, with a last price of $1.24. The SMA 20, SMA 50, and SMA 200 are $1.35, $1.41, and $2.23, respectively, suggesting resistance levels above the current price. The ATR of $0.11 indicates low volatility. From a fundamental perspective, Werewolf Therapeutics has a market cap of $50.80M, with a price-to-book (P/B) ratio of 0.62, indicating potential undervaluation. However, the negative return on equity (RoE) of -69.50% and a high price-to-sales (P/S) ratio of 15.00 signal significant risks and operational challenges. In the next 3 months, HOWL is expected to face resistance near $1.35 and $1.41, with potential downside risks due to the negative earnings and high P/S ratio. However, any positive developments in its clinical trials could act as a catalyst for price movement. The stock is likely to remain range-bound between $1.00 and $1.50, barring any material news.